News

Published on 30 Nov 2021 on Zacks via Yahoo Finance

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing


Article preview image

QIAGEN N.V. QGEN and DiaSorin recently announced the receipt of FDA approval of the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin’s automated LIAISON XS platform. QIAGEN and DiaSorin developed the LIAISON QuantiFERON-TB Gold Plus, an interferon-gamma release assay (IGRA), to provide streamlined laboratory automation for latent tuberculosis (TB) screening. QuantiFERON-TB tests for interferon-gamma generated by T-cells that have encountered TB bacteria.

The recent FDA approval for LIAISON XS platform builds on the already approved use of QuantiFERON-TB assay running on the LIAISON XL platforms in the United States since 2019. This authorization expands U.S. customers’ accessibility to automation solutions for processing QIAGEN’s blood-based test for latent TB detection and facilitates the transition from traditional tuberculin skin tests.

Strategic Significance

NYSE.WST price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical Services, Inc. WST is well poised for growth, backed by the robust Proprietar...

Zacks via Yahoo Finance 14 Mar 2024

Insider Sell: VP, Chief Accounting Officer Chad Winters Sells Shares of West Pharmaceutical ...

West Pharmaceutical Services Inc (NYSE:WST), a global leader in the design and production of cont...

GuruFocus.com via Yahoo Finance 12 Mar 2024

Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic...

Key Insights West Pharmaceutical Services' estimated fair value is US$295 based on 2 Stage Free C...

Simply Wall St. via Yahoo Finance 12 Mar 2024

West Pharmaceutical Services Inc President and CEO Eric Green Sells Company Shares

Eric Green, President, CEO, and Board Chair of West Pharmaceutical Services Inc (NYSE:WST), has s...

GuruFocus.com via Yahoo Finance 1 Mar 2024

Insider Sell: SVP, Chief Technology Officer Silji Abraham Sells 7,012 Shares of West ...

Silji Abraham, SVP, Chief Technology Officer of West Pharmaceutical Services Inc (NYSE:WST), has ...

GuruFocus.com via Yahoo Finance 27 Feb 2024

Decoding West Pharmaceutical Services Inc (WST): A Strategic SWOT Insight

West Pharmaceutical Services Inc (NYSE:WST) exhibits robust financial performance with a strong f...

GuruFocus.com via Yahoo Finance 22 Feb 2024

West Pharmaceutical Services (WST) Fell on Reduced Full Year Guidance

Conestoga Capital Advisors, an asset management company, released its “SMid Cap Strategy” fourth-...

Insider Monkey via Yahoo Finance 19 Feb 2024

Analysts Have Lowered Expectations For West Pharmaceutical Services, Inc. (NYSE:WST) After Its...

There's been a notable change in appetite for West Pharmaceutical Services, Inc. (NYSE:WST) share...

Simply Wall St. via Yahoo Finance 18 Feb 2024

West Pharmaceutical Services' (NYSE:WST) earnings growth rate lags the 28% CAGR delivered to...

West Pharmaceutical Services, Inc. (NYSE:WST) shareholders might be concerned after seeing the sh...

Simply Wall St. via Yahoo Finance 16 Feb 2024

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2023 Earnings Call Transcript

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2023 Earnings Call Transcript February 15, 2024 ...

Insider Monkey via Yahoo Finance 16 Feb 2024